On January 26, 2023, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for adjuvant (additional) treatment following surgery and chemotherapy for stage IB, II, or IIIA non-small cell lung cancer (NSCLC).  This approval was based on the KEYNOTE-091 clinical trial where people who took Keytruda after surgery and chemotherapy lived significantly longer without a recurrence of the cancer than those who did not. This new approval provides another treatment option after surgery for people with early stage NSCLC

Read the full announcement from the FDA here.